Lund-Johansen P
Department of Cardiology, University of Bergen, Norway.
Am J Hypertens. 1993 Jul;6(7 Pt 2):294S-299S. doi: 10.1093/ajh/6.7.294s.
Isradipine is a dihydropyridine calcium antagonist used for the treatment of hypertension. It is highly selective for vascular smooth muscle, more than cardiac muscle, and thus, lowers systemic blood pressure by reducing peripheral vascular resistance. Isradipine has less negative exotropic effect than other available calcium antagonists, and generally does not affect cardiac output, stroke volume, or heart rate when used chronically to treat hypertension. This agent has been shown to reduce left ventricular mass in patients with left ventricular hypertrophy after 5 to 10 months of therapy, without affecting cardiac output. Unlike most other calcium antagonists, isradipine can be used safely in hypertensive patients with congestive heart failure because its use in blood pressure lowering dosages does not compromise pump function. Isradipine has antiischemic properties and, in animals, antiatherosclerotic properties. Generally, it is a safe, well-tolerated agent for the treatment of hypertension with primarily benign effects on the heart.
伊拉地平是一种用于治疗高血压的二氢吡啶类钙拮抗剂。它对血管平滑肌的选择性高于心肌,因此通过降低外周血管阻力来降低全身血压。与其他可用的钙拮抗剂相比,伊拉地平的负性变力作用较小,长期用于治疗高血压时,一般不影响心输出量、每搏输出量或心率。该药物已被证明在治疗5至10个月后可减轻左心室肥厚患者的左心室质量,而不影响心输出量。与大多数其他钙拮抗剂不同,伊拉地平可安全用于充血性心力衰竭的高血压患者,因为以降血压剂量使用时不会损害泵功能。伊拉地平具有抗缺血特性,在动物实验中还具有抗动脉粥样硬化特性。一般来说,它是一种安全、耐受性良好的治疗高血压的药物,对心脏主要产生良性作用。